Quoin Pharmaceuticals Ltd DRC (QNRX) - Total Liabilities
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has total liabilities worth $6.92 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quoin Pharmaceuticals Ltd DRC - Total Liabilities Trend (2015–2025)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's total liabilities have evolved over time, based on quarterly financial data. See QNRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Quoin Pharmaceuticals Ltd DRC Competitors by Total Liabilities
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nyrstar NV
BR:NYR
|
Belgium | €20.26 Million |
|
Encorp Bhd
KLSE:6076
|
Malaysia | RM598.07 Million |
|
Metal Bank Ltd
AU:MBK
|
Australia | AU$334.64K |
|
Jupiter Neurosciences, Inc. Common Stock
NASDAQ:JUNS
|
USA | $7.40 Million |
|
Courtois S.A
PA:COUR
|
France | €9.50 Million |
|
Dundas Minerals Ltd
AU:DUN
|
Australia | AU$1.40 Million |
|
Major Development Public Company Limited
BK:MJD
|
Thailand | ฿13.93 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Quoin Pharmaceuticals Ltd DRC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Quoin Pharmaceuticals Ltd DRC stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quoin Pharmaceuticals Ltd DRC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual total liabilities of Quoin Pharmaceuticals Ltd DRC from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.27 Million | +11.78% |
| 2024-12-31 | $6.50 Million | -0.01% |
| 2023-12-31 | $6.51 Million | -7.74% |
| 2022-12-31 | $7.05 Million | -18.95% |
| 2021-12-31 | $8.70 Million | +8.95% |
| 2020-12-31 | $7.99 Million | +325.43% |
| 2019-12-31 | $1.88 Million | +4.45% |
| 2018-12-31 | $1.80 Million | -45.85% |
| 2017-12-31 | $3.32 Million | +135.52% |
| 2016-12-31 | $1.41 Million | +91.70% |
| 2015-12-31 | $735.02K | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more